Antonio Tursi, Giammarco Mocci, Paolo Usai Satta, Walter Elisei
{"title":"共生混合物对中重度结肠憩室病的影响","authors":"Antonio Tursi, Giammarco Mocci, Paolo Usai Satta, Walter Elisei","doi":"10.2174/0115748871308652240712101604","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Microbial imbalance is thought to play a role in the pathogenesis of Diverticular Disease (DD).</p><p><strong>Objective: </strong>We aimed to assess the efficacy of a symbiotic mixture (Prolactis GG Plus®) in the treatment of moderate to severe DD, scored according to the Diverticular Inflammation and Complication Assessment (DICA) classification.</p><p><strong>Methods: </strong>A retrospective study was conducted enrolling the following patients: at the first diagnosis of DD; in whom DD was diagnosed with colonoscopy and scored according to DICA classification; treated with Prolactis GG Plus® two times/daily for 2 consecutive months; in whom the severity of the abdominal pain was scored with a 10-points visual-analogue scale (VAS) at baseline and the end of follow-up; in whom fecal calprotectin (FC) was assessed at baseline and the end of follow-up as μg/g.</p><p><strong>Results: </strong>Twenty-four patients were identified (10 males, 14 females; 16 as DICA 2, and 8 as DICA 3). Prolactis GG Plus® decreased the severity of abdominal pain both in DICA 2 (p =0.02) and DICA 3 patients (p =0.01), while FC decreased significantly in DICA 2 (p <0.02) but not in DICA 3 (p =0.123) patients. Acute diverticulitis occurred during the follow-up in two DICA 3 patients but none DICA 2 patients. Add-on therapy was required by eight DICA 2 (50%) and six DICA 3 patients (75%).</p><p><strong>Conclusion: </strong>In newly diagnosed patients with DD, the symbiotic mixture Prolactis GG Plus® can be a potential treatment for moderate (DICA 2) DD as a single treatment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon.\",\"authors\":\"Antonio Tursi, Giammarco Mocci, Paolo Usai Satta, Walter Elisei\",\"doi\":\"10.2174/0115748871308652240712101604\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Microbial imbalance is thought to play a role in the pathogenesis of Diverticular Disease (DD).</p><p><strong>Objective: </strong>We aimed to assess the efficacy of a symbiotic mixture (Prolactis GG Plus®) in the treatment of moderate to severe DD, scored according to the Diverticular Inflammation and Complication Assessment (DICA) classification.</p><p><strong>Methods: </strong>A retrospective study was conducted enrolling the following patients: at the first diagnosis of DD; in whom DD was diagnosed with colonoscopy and scored according to DICA classification; treated with Prolactis GG Plus® two times/daily for 2 consecutive months; in whom the severity of the abdominal pain was scored with a 10-points visual-analogue scale (VAS) at baseline and the end of follow-up; in whom fecal calprotectin (FC) was assessed at baseline and the end of follow-up as μg/g.</p><p><strong>Results: </strong>Twenty-four patients were identified (10 males, 14 females; 16 as DICA 2, and 8 as DICA 3). Prolactis GG Plus® decreased the severity of abdominal pain both in DICA 2 (p =0.02) and DICA 3 patients (p =0.01), while FC decreased significantly in DICA 2 (p <0.02) but not in DICA 3 (p =0.123) patients. Acute diverticulitis occurred during the follow-up in two DICA 3 patients but none DICA 2 patients. Add-on therapy was required by eight DICA 2 (50%) and six DICA 3 patients (75%).</p><p><strong>Conclusion: </strong>In newly diagnosed patients with DD, the symbiotic mixture Prolactis GG Plus® can be a potential treatment for moderate (DICA 2) DD as a single treatment.</p>\",\"PeriodicalId\":21174,\"journal\":{\"name\":\"Reviews on recent clinical trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews on recent clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748871308652240712101604\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871308652240712101604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:微生物失衡被认为在憩室疾病(DD)的发病机制中起作用:我们的目的是评估共生混合物(Prolactis GG Plus®)治疗中重度憩室炎的疗效:方法: 进行了一项回顾性研究,纳入了以下患者:首次诊断为 DD;通过结肠镜检查确诊为 DD,并根据 DICA 分级进行评分;连续 2 个月接受普罗拉迪斯 GG Plus® 治疗,每天 2 次;在基线和随访结束时使用 10 点视觉模拟量表(VAS)对腹痛的严重程度进行评分;在基线和随访结束时评估粪便钙蛋白(FC),单位为微克/克:确定了 24 名患者(10 名男性,14 名女性;16 名为 DICA 2,8 名为 DICA 3)。Prolactis GG Plus® 降低了 DICA 2(p =0.02)和 DICA 3(p =0.01)患者腹痛的严重程度,而 FC 在 DICA 2 中显著降低(p 结论:Prolactis GG Plus® 在 DICA 3 中降低了腹痛的严重程度,而 FC 在 DICA 2 中显著降低:对于新确诊的 DD 患者,共生混合物 Prolactis GG Plus® 可作为一种单一疗法治疗中度(DICA 2)DD。
Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon.
Background: Microbial imbalance is thought to play a role in the pathogenesis of Diverticular Disease (DD).
Objective: We aimed to assess the efficacy of a symbiotic mixture (Prolactis GG Plus®) in the treatment of moderate to severe DD, scored according to the Diverticular Inflammation and Complication Assessment (DICA) classification.
Methods: A retrospective study was conducted enrolling the following patients: at the first diagnosis of DD; in whom DD was diagnosed with colonoscopy and scored according to DICA classification; treated with Prolactis GG Plus® two times/daily for 2 consecutive months; in whom the severity of the abdominal pain was scored with a 10-points visual-analogue scale (VAS) at baseline and the end of follow-up; in whom fecal calprotectin (FC) was assessed at baseline and the end of follow-up as μg/g.
Results: Twenty-four patients were identified (10 males, 14 females; 16 as DICA 2, and 8 as DICA 3). Prolactis GG Plus® decreased the severity of abdominal pain both in DICA 2 (p =0.02) and DICA 3 patients (p =0.01), while FC decreased significantly in DICA 2 (p <0.02) but not in DICA 3 (p =0.123) patients. Acute diverticulitis occurred during the follow-up in two DICA 3 patients but none DICA 2 patients. Add-on therapy was required by eight DICA 2 (50%) and six DICA 3 patients (75%).
Conclusion: In newly diagnosed patients with DD, the symbiotic mixture Prolactis GG Plus® can be a potential treatment for moderate (DICA 2) DD as a single treatment.
期刊介绍:
Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.